Dyax (DYAX) Says Sigma-Tau's Taiwan, Singapore, South Korea KALBITOR Rights Eliminated
In a Form 8-K, Dyax (Nasdaq: DYAX) disclosed Sigma-Tau's Defiante Farmaceutica S.A. entered into a third amendment under its joint development and license agreement dated effective as of June 18th, 2010.
The amendment eliminates Sigma-Tau's rights to develop and commercialize KALBITOR (ecallantide) in Taiwan, Singapore and South Korea. This reduction in territories removes Sigma-Tau’s obligations to pay milestones, development costs or other compensation or reimbursement in relation to Taiwan, Singapore and South Korea. As a result, Sigma Tau’s obligation to make an upfront payment of $3 million, which was payable to Dyax under the existing agreement on or before December 31, 2011, as well as downstream milestone and royalty payments related to the eliminated territories, has been terminated.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
The amendment eliminates Sigma-Tau's rights to develop and commercialize KALBITOR (ecallantide) in Taiwan, Singapore and South Korea. This reduction in territories removes Sigma-Tau’s obligations to pay milestones, development costs or other compensation or reimbursement in relation to Taiwan, Singapore and South Korea. As a result, Sigma Tau’s obligation to make an upfront payment of $3 million, which was payable to Dyax under the existing agreement on or before December 31, 2011, as well as downstream milestone and royalty payments related to the eliminated territories, has been terminated.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Dyax Launches HAE Diagnostic Testing Refund Program to Encourage Proper Diagnosis and Disease Management
- Mylan (MYL) Launches Generic Bonviva Tabs (RHHBY) in Italy & the U.K.
- Dow Chemical (DOW) Wins $2.16B in K-Dow Arbitration
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
